



## Prior Authorization Approval Criteria

### Stavzor (valproic acid)

**Generic name:** Valproic acid

**Brand name:** Stavzor

**Medication class:** Anticonvulsant

**FDA-approved uses:**

- Acute treatment of manic episodes associated with bipolar disorder
- Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures.
- Prophylaxis of migraine headaches.

**Available dosage forms:** 125 mg, 250 mg and 500 mg delayed release capsule

**Usual dose:**

- Bipolar disorder, mania: start at 750 mg/day, in divided doses.
- Seizures: Up to 60 mg/kg/day in divided doses.
- Migraine: 250 mg twice daily.

**Approximate cost** (based on AWP 2008): 125 mg: \$99.69/100; 250 mg: \$195.81/100; 500 mg: \$371.08/100

**Duration of therapy:** Indefinite

**Criteria for use** (*bullet points below are all inclusive unless otherwise noted*):

- Patient must be clinically diagnosed with bipolar, seizures, or migraines.
- Patient must have tried and failed generic Depakene (valproic acid).

**Contraindication:**

- Hepatic disease or significant hepatic dysfunction
- Known hypersensitivity to the drug
- Urea cycle disorders

**Not approved if:**

- Patient does not meet the above-stated criteria
- Patient has any contraindications to the use of Stavzor

**Special considerations:**

drug	formulation	dosing frequency	awp
Depakene Syrup	Immediate release syrup	BID to TID dosing	<b>250 mg/5 ml</b> \$285.50/16 oz brand \$14.00/16 oz generic
Depakene Capsule	Immediate release capsule	BID to TID dosing	<b>250 mg</b> \$279.40/100 brand \$79.40/100 generic
Stavzor	Delayed release capsule	BID to TID dosing	<b>125 mg</b> \$99.69/100 <b>250 mg</b> \$195.81/100 <b>500 mg</b> \$371.08/100

FCHP Pharmacy and Therapeutics Committee approval: \_\_\_\_\_

Date: \_\_\_\_\_

Adopted: 12/10/2008